What is Rapport Therapeutics, Inc.'s R&D?

Rapport Therapeutics, Inc. (RAPP) reported R&D of $32.72M in Q1 2026.

How has Rapport Therapeutics, Inc.'s R&D changed year-over-year?

Rapport Therapeutics, Inc.'s R&D increased by 67.2% year-over-year, from $19.57M to $32.72M.

What is the long-term trend for Rapport Therapeutics, Inc.'s R&D?

Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s R&D has grown at a 84.0% compound annual growth rate (CAGR), from $28M to $94.79M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Rapport Therapeutics, Inc. RAPP R&D

R&D at other companies

Bristol-Myers SquibbBMY

$2.65B+17.4%

Supernus PharmaceuticalsSUPN

$39.44M+46.5%

Xenon PharmaceuticalsXENE

$88.51M+44.6%

Praxis Precision Medicines, Inc.PRAX

$77.99M+28.3%

BiohavenBHVN

$103.83M-44.7%

Septerna, Inc.SEPN

$29.54M+53.3%

Segments

By product

See full

RAP219Program External Expenses$15.82M+98.7%

Preclinical Programs External Expenses$4.29M+32.1%

Other Costs$1.97M+24.7%

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.86B+309%

Enterprise value$1.79B+352%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s R&D?: Rapport Therapeutics, Inc. (RAPP) reported R&D of $32.72M in Q1 2026.
How has Rapport Therapeutics, Inc.'s R&D changed year-over-year?: Rapport Therapeutics, Inc.'s R&D increased by 67.2% year-over-year, from $19.57M to $32.72M.
What is the long-term trend for Rapport Therapeutics, Inc.'s R&D?: Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s R&D has grown at a 84.0% compound annual growth rate (CAGR), from $28M to $94.79M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.